MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

Topoisomerase I/II inhibitor 3

CAS No. : 2770804-74-3

MCE 國際站：Topoisomerase I/II inhibitor 3

產(chǎn)品活性：Topoisomerase I/II inhibitor 3 (7) 是一種有效的拓撲異構(gòu)酶 I (Topo I) 和 II (Topo II) 雙抑制劑。Topoisomerase I/II inhibitor 3 通過抑制 PI3K/Akt/mTOR 信號通路抑制細胞增殖、侵襲和遷移，誘導(dǎo)細胞凋亡(apoptosis)。Topoisomerase I/II inhibitor 3 可用于肝癌的研究。

研究領(lǐng)域：Cell Cycle/DNA Damage??|??PI3K/Akt/mTOR??|??Apoptosis??|??NF-κB??|??Metabolic Enzyme/Protease??|??Immunology/Inflammation

作用靶點：Topoisomerase??|??PI3K??|??Apoptosis??|??Reactive Oxygen Species

In Vitro: Topoisomerase I/II inhibitor 3 (compound 7) (0-100 μM) can insert into DNA and change the topology of DNA, cause DNA damage to a certain extent.
Topoisomerase I/II inhibitor 3 (0-4 μM, 24 h) inhibits HCC (hepatocellular carcinoma) cells proliferation in a dose-dependent manner, inhibits migration and invasion of LM9 and HuH7 cells by inhibiting the expression of MMP-9.
Topoisomerase I/II inhibitor 3 (0-14 μM, 48 h) significantly induces the apoptosis of LM9 and HuH7 cells, and induces mitochondrial dysfunction and ROS burst in a dose-dependent manner.
Topoisomerase I/II inhibitor 3 (0-7 μM, 48 h) reduces the expression of the inhibitory factor Bcl-2 and promotes the expression of mitochondria-dependent apoptosis-related proteins such as Bax, cytochrome C, cleaved-caspase-3 and cleaved-caspase-9; inhibits the phosphorylation of PI3K/Akt/mTOR signaling pathway.

In Vivo: Topoisomerase I/II inhibitor 3 (compound 7) (male Kunming mice, 0-400 mg/kg, IP, once) causes the mice in the 400 mg/kg group die, with the LD₅₀ between 250 and 400 mg/kg.

相關(guān)產(chǎn)品：MG-132??|??3-Methyladenine??|??Doxorubicin hydrochloride??|??Bafilomycin A1??|??Tamoxifen??|??RSL3??|??Y-27632??|??Paclitaxel??|??LY294002??|??Z-VAD-FMK??|??H2DCFDA??|??2-Deoxy-D-glucose??|??Acetylcysteine??|??Angiotensin II human??|??Staurosporine??|??Actinomycin D??|??SB-431542??|??5-Fluorouracil??|??MitoSOX Red??|??Bortezomib??|??Oxaliplatin??|??Deferoxamine mesylate??|??Trametinib??|??Sorafenib??|??Gemcitabine??|??Temozolomide??|??Etoposide??|??Rotenone??|??Decitabine??|??Mdivi-1

熱門產(chǎn)品線：重組蛋白? |? 藥物篩選? |? 天然產(chǎn)物? |? 熒光染料? |? PROTAC? |? 同位素標(biāo)記物

Trending products：Recombinant Proteins? |? Bioactive Screening Libraries? |? Natural Products? |? Dye Reagents? |? PROTAC? |? Isotope-Labeled Compounds

品牌介紹:
????MCE (MedChemExpress) 擁有200 多種全球獨家化合物庫，我們致力于為全球科研客戶提供前沿最全的高品質(zhì)小分子活性化合物；
????50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)域；
????產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目；
????提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
????設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
????提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
????產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
????Nature, Cell, Science 等多種頂級期刊及制藥專利收錄了MCE客戶的科研成果；
????專業(yè)團隊跟蹤最新的制藥及生命科學(xué)研究進展，為您提供全球最新的活性化合物；
????與世界各大制藥公司及知名科研機構(gòu)建立了長期的合作。